Insider Selling: Alexion Pharmaceuticals Inc. (ALXN) EVP Sells 4,584 Shares of Stock
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) EVP Carsten Thiel sold 4,584 shares of Alexion Pharmaceuticals stock in a transaction on Friday, October 14th. The stock was sold at an average price of $120.28, for a total value of $551,363.52. Following the sale, the executive vice president now owns 32,741 shares in the company, valued at $3,938,087.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Carsten Thiel also recently made the following trade(s):
- On Monday, October 3rd, Carsten Thiel sold 29 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $122.41, for a total value of $3,549.89.
- On Tuesday, September 13th, Carsten Thiel sold 3,225 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $128.67, for a total value of $414,960.75.
- On Tuesday, September 6th, Carsten Thiel sold 1,000 shares of Alexion Pharmaceuticals stock. The stock was sold at an average price of $125.94, for a total value of $125,940.00.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded up 1.57% during midday trading on Tuesday, hitting $121.34. The stock had a trading volume of 1,130,164 shares. The company has a market capitalization of $27.21 billion, a PE ratio of 304.87 and a beta of 1.33. Alexion Pharmaceuticals Inc. has a 1-year low of $110.56 and a 1-year high of $193.45. The stock’s 50-day moving average is $125.47 and its 200-day moving average is $134.10.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/insider-selling-alexion-pharmaceuticals-inc-alxn-evp-sells-4584-shares-of-stock.html
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing the Zacks’ consensus estimate of $1.17 by $0.04. The business had revenue of $753 million for the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. Alexion Pharmaceuticals’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.44 earnings per share. Equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $4.67 EPS for the current year.
A number of analysts recently commented on ALXN shares. Vetr upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating and set a $107.00 price target on the stock in a report on Thursday, September 29th. Piper Jaffray Cos. restated an “overweight” rating and issued a $185.00 target price on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 16th. SunTrust Banks Inc. lowered their target price on Alexion Pharmaceuticals from $220.00 to $197.00 and set a “buy” rating on the stock in a research note on Wednesday, July 13th. Citigroup Inc. boosted their target price on Alexion Pharmaceuticals from $154.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, September 20th. Finally, FBR & Co assumed coverage on Alexion Pharmaceuticals in a research note on Thursday, September 15th. They issued an “underperform” rating on the stock. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $176.10.
A number of large investors have recently bought and sold shares of ALXN. Legal & General Group Plc boosted its stake in Alexion Pharmaceuticals by 4.0% in the first quarter. Legal & General Group Plc now owns 920,520 shares of the biopharmaceutical company’s stock worth $128,153,000 after buying an additional 35,267 shares in the last quarter. Zurich Insurance Group Ltd FI boosted its stake in Alexion Pharmaceuticals by 55.2% in the first quarter. Zurich Insurance Group Ltd FI now owns 34,580 shares of the biopharmaceutical company’s stock worth $4,814,000 after buying an additional 12,298 shares in the last quarter. National Pension Service boosted its stake in Alexion Pharmaceuticals by 4.2% in the first quarter. National Pension Service now owns 119,843 shares of the biopharmaceutical company’s stock worth $16,685,000 after buying an additional 4,811 shares in the last quarter. Dodge & Cox acquired a new stake in Alexion Pharmaceuticals during the first quarter worth approximately $253,000. Finally, Mariner Wealth Advisors LLC boosted its stake in Alexion Pharmaceuticals by 17.6% in the first quarter. Mariner Wealth Advisors LLC now owns 10,068 shares of the biopharmaceutical company’s stock worth $1,402,000 after buying an additional 1,508 shares in the last quarter. 96.36% of the stock is currently owned by institutional investors and hedge funds.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.